Trevi Therapeutics Inc. Insider Trading

TRVI

Last 12 months

Insiders sold 596K and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in May 2019.

Net open-market

−596K

0 buys · 1 sale

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 1

executives and directors

Last open-market buy

May 2019

May 9, 2019

Get an email when TRVI's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 15	Michael Thomas Heffernan Director	Sold10b5-1 plan 4 parts	39,473	$15.09 average	596K	86%	Form 4
Mar 25, 2025	Thomas Sciascia Chief Scientific Officer	SoldNo plan	2,631	$6.60	17K	1.2%	Form 4
Mar 21, 2025	Jennifer L Good President & CEO	SoldNo plan	5,263	$6.58	35K	2.4%	Form 4
Mar 10, 2025	Farrell Simon Chief Commercial Officer	Sold10b5-1 plan 2 parts	81,313	$6.75 average	549K	51%	Form 4

Sep 1510b5-1 plan
Michael Thomas Heffernan
Director · sold 39,473 at avg $15.09
596K
86% of stake
Mar 25, 2025No plan
Thomas Sciascia
Chief Scientific Officer · sold 2,631 at $6.60
17K
1.2% of stake
Mar 21, 2025No plan
Jennifer L Good
President & CEO · sold 5,263 at $6.58
35K
2.4% of stake
Mar 10, 202510b5-1 plan
Farrell Simon
Chief Commercial Officer · sold 81,313 at avg $6.75
549K
51% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TRVI, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with TRVI

CompareIntrinsic value

CPHIChina Pharma Holdings Inc.

$0.59-3.28%15

BFRIBiofrontera Inc.

$0.90+1.55%30

TBPHTheravance Biopharma Inc.

No recent price82

MDGLMadrigal Pharmaceuticals, Inc.

$400.67+1.10%10

ATNMActinium Pharmaceuticals Inc.

$1.41+0.71%30

KPRXKiora Pharmaceuticals Inc.

$1.66-4.05%10

OGENOragenics Inc.

$0.37+0.00%20

ISCOInternational Stem Cell Corporation

$0.14+0.00%29

Held by ETFs

TRVI is in 31 US ETFs. The largest of them, with TRVI's weight in each:

Spot a number that looks wrong? Check it in TRVI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TRVI

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.